![]() | Up a level |
2022
Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M. J., Arcila, M. E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A. M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Janne, P. A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I. I., Wolf, J., Wu, Y. L., Yang, S. R., Yang, J. C. H., Yatabe, Y., Pentheroudakis, G. and Peters, S. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol., 33 (5). S. 466 - 488. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2021
Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Font, E. F., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. (2021). CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation. J. Thorac. Oncol., 16 (1). S. S29 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Schuler, M., Li, B. T., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G. K., Price, T., Borghaei, H., Kato, T., Takahashi, T., Spira, A., Ramalingam, S., Besse, B., Barlesi, F., Tran, Q., Henary, H., Ngarmchamnanrith, G., Govindan, R. and Wolf, J. (2021). Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis. Pneumologie, 75. S. S38 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790
2016
Lena, H., Rizvi, N. A., Wolf, J., Cappuzzo, F., Zalcman, G., Baas, P., Mazieres, J., Farsaci, B., Blackwood-Chirchir, M. A. and Ramalingam, S. (2016). Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profiling analyses. J. Thorac. Oncol., 11 (4). S. S115 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380